|
INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution
|
14 Jun, 2021 |
|
INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from USAN
|
02 Jun, 2021 |
|
INmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021
|
24 May, 2021 |
|
INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update
|
05 May, 2021 |
|
INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, May 5
|
28 Apr, 2021 |
|
INmune Bio, Inc. Announces Participation in Fireside Chat at the B Riley Neurosciences Conference
|
26 Apr, 2021 |
|
INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical Meetings
|
22 Mar, 2021 |
|
INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021
|
08 Mar, 2021 |
|
INmune Bio, Inc. Announces Fourth Quarter and Full Year 2020 Results and Provides Business Update
|
04 Mar, 2021 |
|
INmune Bio, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on Thursday, March 4
|
25 Feb, 2021 |
|
INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial
|
21 Jan, 2021 |
|
INmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at 8 AM ET
|
13 Jan, 2021 |
English
Chinese (Simplified)